Thus, at this stage we cannot exclude potential off-targets effects by SMS121, but we can conclude that it targets CD36, inhibits CD36 activity (inhibit lipid uptake) and decreases the viability of AML cells. This evidence concerns the gene CD36 and acute myeloid leukemia.